Endocrine Abstracts

Introduction: thyroid carcinoma is an uncommon malignancy, but it’s incidence appears to be increasing slowly (female 2–3.8/100.000 - male 1.2–2.6/100.000). This is the most common malignant endocrine tumour, represents about 1% of all malignancies. The majority of these patients females, mostly between the age of 30–60. The main differentiated histological types are papillary and follicular. The options of the treatment are surgical removal (mainly total),...

Background: Current available data demonstrate the ability of somatostatin analogues (Ssan) to reduce tumoral size in GH-secreting pituitary adenomas. Somatostatin receptors are present on both tumour cells and vascular endothelium; therefore, potential mechanisms for tumour shrinkage with Ssan include inhibition of cell proliferation, increased cell loss, and inhibition of angiogenesis.Objective: To assess the mechanisms for tumour shrinkage in GH-secre...

Background: It is well established that 1,25-dihydroxyvitamin D3 (1,25-D3) inhibits cell growth and induces apoptosis in numerous tumors. Increased expression of 1,25-D3 inactivating enzyme, (24-hydroxylase - CYP24A1), has been observed in numerous thyroid cancer cell lines after calcitriol treatment in vitro. We examined the expression of CYP24A1 as well as the activating 1-α-hydroxylase (CYP27B1) gene in human thyroid cancer tissue.Methods:...

It is established that somatic oncogene mutation (BRAF, NRAS, HRAS, KRAS) and gene translocations (RET/PTC, PAX8/PPAR-gamma) are associated with the development of thyroid cancer. Somatic single nucleotide polymorphisms were analyzed by LigthCycler melting method, while translocations were identified by real-time polymerase chain reaction technique. In 22 intraoperative thyroid tissue samples (11 pathologic and 11 normal). In tumorous sample 3 BRAF, 2 NRAS and one HRAS mutatio...